Follow
Rudolf de Boer, RA de Boer
Rudolf de Boer, RA de Boer
Professor in Cardiology, Erasmus MC, Rotterdam, the Netherlands
Verified email at erasmusmc.nl - Homepage
Title
Cited by
Cited by
Year
Heart disease and stroke statistics—2017 update: a report from the American Heart Association
EJ Benjamin, MJ Blaha, SE Chiuve, M Cushman, SR Das, R Deo, ...
circulation 135 (10), e146-e603, 2017
247372017
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart …
TA McDonagh, M Metra, M Adamo, RS Gardner, A Baumbach, M Böhm, ...
European heart journal 42 (36), 3599-3726, 2021
89442021
Dapagliflozin in patients with heart failure and reduced ejection fraction
JJV McMurray, SD Solomon, SE Inzucchi, L Køber, MN Kosiborod, ...
New England Journal of Medicine 381 (21), 1995-2008, 2019
55312019
How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the …
B Pieske, C Tschöpe, RA De Boer, AG Fraser, SD Anker, E Donal, ...
European heart journal 40 (40), 3297-3317, 2019
13962019
Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction
SD Solomon, JJV McMurray, B Claggett, RA de Boer, D DeMets, ...
New England Journal of Medicine 387 (12), 1089-1098, 2022
11282022
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology …
AR Lyon, T López-Fernández, LS Couch, R Asteggiano, MC Aznar, ...
European Heart Journal-Cardiovascular Imaging 23 (10), e333-e465, 2022
10712022
Identification of seven loci affecting mean telomere length and their association with disease
V Codd, CP Nelson, E Albrecht, M Mangino, J Deelen, JL Buxton, ...
Nature genetics 45 (4), 422-427, 2013
9612013
Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction
RA de Boer, DJA Lok, T Jaarsma, P van der Meer, AA Voors, HL Hillege, ...
Annals of medicine 43 (1), 60-68, 2011
7932011
Galectin‐3: a novel mediator of heart failure development and progression
RA de Boer, AA Voors, P Muntendam, WH van Gilst, DJ van Veldhuisen
European journal of heart failure 11 (9), 811-817, 2009
7852009
Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association …
PM Seferovic, P Ponikowski, SD Anker, J Bauersachs, O Chioncel, ...
European journal of heart failure 21 (10), 1169-1186, 2019
7192019
Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND
FP Brouwers, RA de Boer, P van der Harst, AA Voors, RT Gansevoort, ...
European heart journal 34 (19), 1424-1431, 2013
6502013
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology
PM Seferović, MC Petrie, GS Filippatos, SD Anker, G Rosano, ...
European journal of heart failure 20 (5), 853-872, 2018
6412018
Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations
C Mueller, K McDonald, RA de Boer, A Maisel, JGF Cleland, ...
European journal of heart failure 21 (6), 715-731, 2019
6152019
The ATLAS experiment at the CERN large hadron collider
A Collaboration, G Aad, E Abat, J Abdallah, AA Abdelalim, A Abdesselam, ...
Jinst 3, S08003, 2008
5802008
Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association
SL Chow, AS Maisel, I Anand, B Bozkurt, RA De Boer, GM Felker, ...
Circulation 135 (22), e1054-e1091, 2017
5632017
Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis
L Yu, WPT Ruifrok, M Meissner, EM Bos, H Van Goor, B Sanjabi, ...
Circulation: Heart Failure 6 (1), 107-117, 2013
5362013
The fibrosis marker galectin‐3 and outcome in the general population
RA De Boer, DJ Van Veldhuisen, RT Gansevoort, AC Muller Kobold, ...
Journal of internal medicine 272 (1), 55-64, 2012
4902012
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the C …
AR Lyon, S Dent, S Stanway, H Earl, C Brezden‐Masley, A Cohen‐Solal, ...
European journal of heart failure 22 (11), 1945-1960, 2020
4862020
New gene functions in megakaryopoiesis and platelet formation
C Gieger, A Radhakrishnan, A Cvejic, W Tang, E Porcu, G Pistis, ...
Nature 480 (7376), 201-208, 2011
4772011
Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of …
PA Van Der Zwaag, IAW Van Rijsingen, A Asimaki, JDH Jongbloed, ...
European journal of heart failure 14 (11), 1199-1207, 2012
4602012
The system can't perform the operation now. Try again later.
Articles 1–20